Heart failure & cardiomyopathies
Safety and feasibility of the eLym™ system for interstitial decongestion in acute decompensated heart failure: primary results of the DELTA-HF trial
Authors' conclusion
eLym therapy in ADHF appeared to be safe, with early data suggesting effective, durable decongestion and a low 6-month rehospitalization rate.
Study context
- Population
- Patients with acute decompensated heart failure (ADHF) on home daily loop diuretic dose equivalent to ≥80 mg furosemide
- Participants
- 40 patients
- Outcome
- Safety and effectiveness of the eLym System
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
- Freedom from device- or procedure-related serious adverse events
- 95%
- Successful device deployment
- all cases
- Weight decrease during eLym therapy (kg)
- 3.6±2.4
- Weight decrease at discharge (kg)
- 6.8±3.4
- Median modified EVEREST Clinical Congestion Score: baseline 5.0 (4.0-6.0), after eLym 2.0 (1.0-4.0), discharge 0 (0-1.0); stable through 6 months
- p-values <0.0001
Further findings
HF hospitalizations and deaths · 6 months
- Patients with HF hospitalizations (3 hospitalizations)
- 2
- Deaths (4 CV, 1 urosepsis)
- 5
Safety
Device- or procedure-related serious adverse events
- Vascular complication causing mediastinal hematoma and death
- 1
- Inotropes required due to hypotension
- 1
Original publication
Safety and feasibility of the eLym™ system for interstitial decongestion in acute decompensated heart failure: primary results of the DELTA-HF trial. Eur J Heart Fail. Published 10 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →